# A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)

NCT07253259

| | |
|---|---|
| **Status** | RECRUITING |
| **Phase** | Early Phase 1 |
| **Sponsor** | Grit Biotechnology |
| **Enrollment** | 36 participants |

## Key Eligibility Criteria

### Inclusion (12)

- Participants or their legal representatives voluntarily sign a written informed consent form, are willing and able to comply with the procedures of this study.
- Aged 18 to 65 years old (inclusive) when signing the informed consent, regardless of gender.
- Participants must meet the following criteria:
- The subjects are allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients with active chronic graft-versus-host disease (active cGVHD) requiring systemic immunosuppressive therapy.
- The subjects are patients with refractory or relapsed active cGVHD after receiving at least two lines of systemic treatment.

... and 7 more (see full listing online)

### Exclusion (10)

- Evidence of recurrence of underlying malignant tumors or post-transplant lymphoproliferative disorder (PTLD) at the time of screening
- Having a history of severe hypersensitivity or allergies
- Suffering from the following heart diseases:
- New York Heart Association (NYHA) Class III or IV congestive heart failure;
- A myocardial infarction occurred or coronary artery bypass surgery was performed within 6 months before the screening period.

... and 5 more (see full listing online)

## Locations (1 total)

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China